Unlike some European countries that have started pilot studies evaluating the implementation of a risk-stratified population-based approach to prostate cancer screening [3], prostate-specific antigen (PSA) testing in the UK remains largely opportunistic, depending on primary care practices or community-led programs [4]. This evidence concerns the gene KLK3 and prostate carcinoma.